Full Press Release Details
Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital
and Updates on New China Strategy
Singapore - (November 6, 2025) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed"
or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary
technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers,
including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank
Pte Ltd ("LongevityBank") from ICH Capital Pte Ltd ("ICH Capital").
the announcement dated August 28, 2025, the strategic vision is for LongevityBank to focus on autologous (using one's own blood,
cells and/or tissues) therapies leveraging its personalized cellular banking services while parent company, CytoMed focuses on donor
blood-derived allogeneic (using donated blood, cells and/or tissues) therapies which already has an approved IND Phase I clinical trial
ongoing in Singapore and a Phase II Investigator-Initiated Trial (IIT) in India. Allogeneic therapies have the advantage of treatment
speed, accessibility and cost-effectiveness. Autologous therapies are less likely to be rejected by one's own immune system and
are better tolerated with higher acceptance level by the immune systems of patients albeit more costly than allogeneic therapies.
is pleased to announce ICH Capital has agreed to invest up to US$500,000 for a 10.0% post-money stake in LongevityBank. Founded in 2001,
ICH Capital is a well-known Singapore-based investment firm that provides cross-border wealth and asset management solutions for ultra-high
net worth individuals and institutions across Asia-Pacific.
Capital's Chairman Vincent Toe remarked "Through LongevityBank, a strategic new subsidiary of CytoMed, ICH Capital gains
relevant exposure into the end-to-end solutions of cell banking and autologous cell therapies. We believe this is the future of healthcare
and LongevityBank is well positioned to be a leading player in Southeast Asia."
capitalize on rapidly growing medical tourism in low cost-Southeast Asia and to prepare for positive regulatory changes, we are exploring
with potential investors and authorities on setting up a joint venture cancer care centre offering both conventional cancer treatments
and the new cell therapy modalities. Interested investors are welcome to contact us. We are also exploring the possibility of offering
free access to our clinical trial participation to our shareholders and their spouses who have no alternative treatment options, subject
to relevant doctors' approval.
State Council Decree No. 818 released on October 10, 2025 establishes a definitive regulatory pathway from clinical research to reimbursable
clinical application for cell therapies. The key distinction is that these therapies are to be regulated as biotechnological medical
procedures under a clinical study to clinical application' pathway within the health system, rather than following the traditional
drug registration process. "This approach creates a mechanism for approved therapies to be incorporated into medical service pricing
systems, providing a tailored and timely opportunity for CytoMed to introduce its patented, off-the-shelf allogeneic gamma delta T cell
platform to China." stated Peter Choo the Chairman of CytoMed.
is in discussion with multiple Chinese companies to jointly develop and commercialize a new method using non-cellular cytokines to manufacture
donor-derived unmodified allogeneic gamma delta T cells in China at low cost.
proprietary gamma delta T cell technology and the associated chimeric antigen receptor gamma delta T cell (CAR- T cell)
technology have been granted a patent by the China National Intellectual Property Administration (CNIPA). The Company is conducting an
Investigational New Drug (IND) first-in-human Phase I clinical trial in Singapore at the National University Hospital Singapore.
Therapeutics Limited (CytoMed)
in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development
agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies,
namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for
the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T
therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating
("X") @CytomedSG, on LinkedIn, and Facebook.
press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions
and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will,
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results
to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject
to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product
candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical
trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements
and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates
on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions
underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes
no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date
Therapeutics Limited
: Evelyn Tan, Chief Corporate Officer